Endpoints News 生物医药· Elizabeth Cairns·· 11 天前AI 评分35
Boehringer 将申请 survodutide 用于肥胖症的批准
#AHA26: Boehringer to seek approval of obesity shot, but gaining market share could be tricky
AI 导读
Boehringer Ingelheim 计划明年为 incretin 注射药 survodutide 申请肥胖症适应症的批准。试验结果显示该药不会增加患者肥胖风险。
正文
Boehringer Ingelheim will seek approval for its incretin shot survodutide for obesity next year, after a trial showed that the drug doesn’t increase patients’ risk …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news